NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $1.28 +0.03 (+2.25%) (As of 09:52 AM ET) Add Compare Share Share Today's Range$1.23▼$1.2850-Day Range$1.01▼$1.6952-Week Range$0.98▼$1.89Volume3,914 shsAverage Volume94,220 shsMarket Capitalization$39.98 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Co-Diagnostics alerts: Email Address Co-Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside60.0% Upside$2.00 Price TargetShort InterestHealthy1.13% of Shares Sold ShortDividend StrengthN/ASustainability-1.10Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.33) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 starsMedical Sector233rd out of 879 stocksSurgical & Medical Instruments Industry30th out of 95 stocks 3.0 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.13% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently decreased by 2.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCo-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Co-Diagnostics is -1.10. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Co-Diagnostics this week, compared to 1 article on an average week.Search Interest5 people have searched for CODX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to grow in the coming year, from ($1.33) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Theo TradeDividends are costing you money!Retirement should be a time of relaxation and financial security, but rising inflation is threatening that idea for many Americans. Traditional income from sources like dividends and bonds are struggling to keep pace with the increasing costs of living, leaving many wondering how to maintain their standard of living. That’s where Ultima Trades can help!Click here to download the eBook now and take control of your financial future. About Co-Diagnostics Stock (NASDAQ:CODX)Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More CODX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CODX Stock News HeadlinesJuly 2, 2024 | prnewswire.comCo-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. StatesJune 18, 2024 | prnewswire.comCo-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21July 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.June 14, 2024 | prnewswire.comCo-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro PlatformMay 13, 2024 | finance.yahoo.comCo-Diagnostics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comCo-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comCODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | prnewswire.comCo-Diagnostics, Inc. Reports First Quarter 2024 Financial ResultsJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.April 25, 2024 | prnewswire.comCo-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and WebcastApril 24, 2024 | prnewswire.comCo-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in TaiwanApril 17, 2024 | morningstar.comCo-Diagnostics Inc Registered ShsApril 12, 2024 | prnewswire.comCo-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting EventApril 4, 2024 | prnewswire.comCo-Diagnostics, Inc. Appoints New President and Other C-Level PositionsMarch 21, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote AddressMarch 18, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, EnglandMarch 17, 2024 | uk.finance.yahoo.comA Look At The Intrinsic Value Of Edel SE & Co. KGaA (ETR:EDL)March 17, 2024 | uk.news.yahoo.comHolby City star Rosie Marcel calls for Casualty not to kill off CharlieSee More Headlines Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CODX CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+60.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-582.36% Pretax Margin-589.77% Return on Equity-42.35% Return on Assets-38.55% Debt Debt-to-Equity RatioN/A Current Ratio10.19 Quick Ratio9.90 Sales & Book Value Annual Sales$6.81 million Price / Sales5.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.44Miscellaneous Outstanding Shares31,280,000Free Float30,527,000Market Cap$39.10 million OptionableOptionable Beta-0.82 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Dwight H. Egan (Age 71)Chairman & CEO Comp: $415.75kMr. Brian L. Brown CPA (Age 48)CFO & Company Secretary Comp: $338.92kMr. Richard David Abbott (Age 52)President Dr. Brent C. Satterfield Ph.D. (Age 47)Co-Founder & Member of Scientific Advisory Board Comp: $237.5kMr. David NielsenChief Operating OfficerMr. Dan Bohrer CPAVice President of Finance & AccountingMr. Christopher ThurstonChief Technology OfficerDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDAlpha Tau MedicalNASDAQ:DRTSClearPoint NeuroNASDAQ:CLPTTriSalus Life SciencesNASDAQ:TLSIQuipt Home MedicalNASDAQ:QIPTView All CompetitorsInstitutional OwnershipSMI Advisory Services LLCBought 20,590 shares on 4/15/2024Ownership: 0.122%View All Institutional Transactions CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 6.0% and is now trading at $1.25. View the best growth stocks for 2024 here. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.10. The business had revenue of $0.47 million for the quarter, compared to analysts' expectations of $3.10 million. Co-Diagnostics had a negative net margin of 582.36% and a negative trailing twelve-month return on equity of 42.35%. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and iBio (IBIO). This page (NASDAQ:CODX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
